On July 18, 2022, the Cooperation Exchange Conference titled "New Policy, New Model, Co-development and sharing of SUP Ecology" jointly organized by SUP and Zhejiang Health Medicine Development was successfully held.

Mr. Qi Guohui, the Chairman of Zhejiang Health Medicine Development, along with his team, attended the cooperation exchange conference and introduced the company's development history and notable achievements. Established in 1993, Zhejiang Health Medicine Development is an innovative pharmaceutical enterprise specializing in drug promotion and market development. The company adheres to the <i>Four Specializations<i> development philosophy of "professionally creating a portfolio of self-operated drugs, focusing on long-term profitability for retail distributors, dedicatedly developing and nurturing the market, and sincerely serving customers". It has consistently followed the path of "creating value for end customers".

Ms. Hu Lingrong, from Branding Department of SUP, provided a detailed introduction to the attending guests about SUP's positioning, advantages, global products, company layout, and corporate culture.

In recent days, the bidding process for the seventh batch of national VBP has concluded. Although the average price reduction in this round of procurement is 48%, which is somewhat alleviated compared to previous rounds, many highly anticipated products saw prices fall beyond expectations. Mr. Wu Ying, from SUP's Eastern Regional Marketing Center, delivered a keynote speech titled "New Policies, New Models, New Blue Ocean" to the attending guests. He shared SUP's close adherence to the new procurement policies, as well as the establishment of the SUP ecosystem, which includes global drug import, drug registration services, omni-channel marketing services, supply chain management services, and professional financial and taxation services. As the first domestic one-stop solution provider for global drug distribution and management, SUP tailors specialized and diversified services based on customer needs.

Postpartum hemorrhage is the leading cause of maternal mortality. With the continuous optimization and implementation of favorable childbirth policies, an increasing number of families are ignited with the desire for childbirth. The cumulative demand for childbirth is being released, leading to a higher proportion of older and high-risk pregnant women. This trend has resulted in a growing clinical demand for high-quality and cost-effective postpartum hemostatic drugs.

Ms. Sun Chaoyang from SUP's Marketing Department presented to the attending guests the product knowledge of Carboprost Tromethamine Injection, which is currently the only FDA-certified product introduced by SUP. This injection is widely used in clinical settings for the prevention and emergency treatment of postpartum hemorrhage in high-risk pregnant women, aiding healthcare professionals in safeguarding the lives of expectant mothers.

Zhejiang Health Medicine Development has been deeply involved in the field of obstetrics and gynecology for many years, accumulating a wealth of experience in operating obstetric products.

During the meeting, everyone's enthusiasm was high as they engaged in in-depth discussions on the clinical application opportunities, customer perspectives, mechanism advantages, and adverse reaction handling of Carboprost Tromethamine Injection. They clarified the development strategy for this product in the Zhejiang market. Both parties will adhere to the cooperative concept of "working together to research and develop, and jointly cultivating the Zhejiang market", and open up a new path of "strategic mutual trust and complementary advantages" for development.

Drug Information

[Drug Name] Carboprost Tromethamine Injection

[Indications]

This product is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion:

1. Failure of expulsion of the fetus during the course of treatment by another method;

2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity;

3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus;

4. nadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.

This product is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of this product has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, this product used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention.

[Dosage and Administration]

1. Abortion and Indications 1–4:

An initial dose of 1 mL of carboprost tromethamine sterile solution (containing the equivalent of 250 micrograms of carboprost) is to be administered deep in the muscle with a tuberculin syringe. Subsequent doses of 250 micrograms should be administered at 11⁄2 to 31⁄2 hour intervals depending on uterine response.

An optional test dose of 100 micrograms (0.4 mL) may be administered initially. The dose may be increased to 500 micrograms (2 mL) if uterine contractility is judged to be inadequate after several doses of 250 micrograms (1 mL).

The total dose administered of carboprost tromethamine should not exceed 12 milligrams and continuous administration of the drug for more than two days is not recommended.

2. For Refractory Postpartum Uterine Bleeding:

An initial dose of 250 micrograms of carboprost tromethamine sterile solution (1 mL of this product) is to be given deep, intramuscularly.

The total dose of this product should not exceed 2 milligrams (8 doses).

[Specification] 250 µg 1ml / branch

[Storage] refrigerate at 2~8℃.

[Packaging] 10 pieces / box

[Shelf life] 48 months

[Production enterprise] Dr. Reddy's Laboratories Limited

[CDE Acceptance Number] JYHS2100039

[China exclusive distributor] Sino Universal Pharmaceutical Co., Ltd